Hsiao Lieu Net Worth

The estimated Net Worth of Hsiao D Lieu is at least $277 Mille dollars as of 5 October 2021. Hsiao Lieu owns over 2,000 units of Ngm Biopharmaceuticals Inc stock worth over $3,080 and over the last 4 years he sold NGM stock worth over $274,299. In addition, he makes $0 as Senior Vice President e Chief Medical Officer at Ngm Biopharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Hsiao Lieu NGM stock SEC Form 4 insiders trading

Hsiao has made over 3 trades of the Ngm Biopharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of NGM stock worth $24,120 on 5 October 2021.

The largest trade he's ever made was selling 10,258 units of Ngm Biopharmaceuticals Inc stock on 11 August 2021 worth over $239,935. On average, Hsiao trades about 1,382 units every 51 days since 2020. As of 5 October 2021 he still owns at least 2,000 units of Ngm Biopharmaceuticals Inc stock.

You can see the complete history of Hsiao Lieu stock trades at the bottom of the page.

Hsiao Lieu biography

Dr. Hsiao D. Lieu M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Prior to NGM, Dr. Lieu worked at Genentech from November 2017 to March 2019 as Vice President of Early Clinical Development for all non-oncology molecules. He also worked at Eli Lilly and Company from July 2012 through November 2017, where he held various leadership roles, most recently as Global Brand Development Leader, Autoimmune, Taltz®. Prior to joining Eli Lilly and Company, Dr. Lieu was a co-founder and Chief Executive Officer of RetinoRx, LLC, Chief Medical Officer and Executive Vice President at Niles Therapeutics, Inc. and held clinical development leadership roles with Portola Pharmaceuticals, Inc. and CV Therapeutics, Inc. (acquired by Gilead). Dr. Lieu was an attending cardiologist at San Francisco General Hospital from 2002 to 2013 and an adjunct Associate Clinical Medical Professor at University of California, San Francisco. Dr. Lieu received his M.D. from Albert Einstein College of Medicine and B.A. from New York University.

How old is Hsiao Lieu?

Hsiao Lieu is 49, he's been the Senior Vice President e Chief Medical Officer of Ngm Biopharmaceuticals Inc since 2019. There are 14 older and 3 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.

What's Hsiao Lieu's mailing address?

Hsiao's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Ngm Biopharmaceuticals Inc

Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel e Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.

What does Ngm Biopharmaceuticals Inc do?

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work

Complete history of Hsiao Lieu stock trades at Ngm Biopharmaceuticals Inc

Ngm Biopharmaceuticals Inc executives and stock owners

Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Woodhouse,
  Chief Executive Officer, Director
• Jin-Long Chen,
  Founder, Chief Scientific Officer, Director
• William Rieflin,
  Executive Chairman of the Board of Directors
• Suzanne Hooper,
  Independent Director
• Dr. David J. Woodhouse Ph.D.,
  CEO & Director
• Dr. Jin-Long Chen Ph.D.,
  Founder, Chief Scientific Officer & Director
• Shelly Guyer,
  Independent Director
• Siobhan Nolan Mangini,
  CFO and Principal Financial & Accounting Officer
• McHenry Tichenor,
  Independent Director
• David Goeddel,
  Lead independent director
• David Schnell,
  Independent Director
• Mark Leschly,
  Independent Director
• William J. Rieflin J.D.,
  Exec. Chairman of Directors
• Siobhan Mangini,
  Chief Financial Officer
• Carole Ho,
  Independent Director
• Hsiao Lieu,
  Senior Vice President, Chief Medical Officer
• Marc Learned,
  Vice President - Research Operations
• Hui Tian,
  Senior Vice President - Research
• Wenyan Shen,
  Senior Vice President - Biologics and CMC
• Alex DePaoli,
  Senior Vice President, Chief Translational Officer
• Valerie Pierce,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Hsiao Dee Lieu,
  Chief Medical Officer & Sr. VP
• Brian Muma,
  VP of HR
• Valerie L. Pierce J.D.,
  Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Alexander Duke Schwartz,
  Exec. Director of Investor Relations
• Group L Ptcg Opportunity Ii...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L P Svennilson Peter ...,
  
• Peter Svennilson,
  Director
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Aetna Wun Trombley,
  President & COO
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Ii, L...,
  
• Group L P Ponoi Capital Ii,...,
  
• Group L Pcolumn Group Iii, ...,
  
• Roger M Perlmutter,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Jean Frederic Viret,
  Chief Financial Officer
• Group Gp, Lpcolumn Group Ii...,
  
• Opportunity Iii Gp, Llc Tcg,
  10% owner
• Irene Perlich,
  Principal Accounting Officer